Publication Listing for the MeSH term bladder cancer. Found 18 abstracts

Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 Feb 19;26(8):2241-2256e4.

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer. 2019 May 31;125(18):3155-63.

Satyal U, Srivastava A, Abbosh PH. Urine Biopsy-Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer. Frontiers in oncology. 2019 Jan;9:1266.   PMCID: PMC6877686

Abbosh PH, Plimack ER. Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2018 Jan 20;4(1):9-18.   PMCID: PMC5798524

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018 May 15;124(10):2115-24.

Klaassen Z, Arora K, Goldberg H, Chandrasekar T, Wallis CJ, Sayyid RK, Fleshner NE, Finelli A, Kutikov A, Violette PD, Kulkarni GS. Extended Venous Thromboembolism Prophylaxis After Radical Cystectomy: A Call for Adherence to Current Guidelines. J Urol. 2017 Nov 04;.

Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY, Retrospective International Study of Cancers of the Urothelium I. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin Appl Thromb Hemost. 2017 Oct;23(7):755-60.

Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY, Risc Investigators. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer medicine. 2017 Jan;6(1):186-94.   PMCID: PMC5269690

Tong C, Daskalakis N, Edwards DC, Cahn DB, Belkoff L, Geynisman DM. Malignant Infiltration of the Penis From Urothelial Carcinoma of the Bladder. Urology. 2017 Sep;107:23-5.   PMCID: Review

Uzzo RG, Horwitz EM, Plimack ER. Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncol. 2016 Feb 17;12(7):887-91.

Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115

Corcoran AT, Handorf E, Canter D, Tomaszewski JJ, Bekelman JE, Kim SP, Uzzo RG, Kutikov A, Smaldone MC. Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU international. 2015 Feb;115(2):230-7.

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.

Ibragimova I, Dulaimi E, Slifker MJ, Chen DY, Uzzo RG, Cairns P. A global profile of gene promoter methylation in treatment-naive urothelial cancer. Epigenetics. 2014 May;9(5):760-73.   PMCID: Pmc4063835

Hoffman AM, Cairns P. Epigenetics of kidney cancer and bladder cancer. Epigenomics. 2011 Feb;3(1):19-34.   PMCID: NIHMS362391

Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU international. 2011 Jul;108(2B):E84-E90.   PMCID: PMC3116980

Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. International Journal of Radiation Oncology Biology Physics. 2005 Jan;62(2):309-17.

Mason TJ, Walsh WP, Lee K, Vogler W. New opportunities for screening and early detection of bladder cancer. Journal of cellular biochemistry. 1992 Jan;50(SUPPL. 16 I):13-22.

The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

bladder cancer urothelial carcinoma radical cystectomy cisplatin immunotherapy venous thromboembolism methylome chemotherapy upper tract urothelial carcinoma mortality pathology Urinary Bladder Neoplasms neoadjuvant chemotherapy Neoadjuvant Therapy precision medicine therapeutic use CPG ISLAND METHYLATION administration & dosage Multicenter Studies as Topic urothelial cancer metastatic urothelial carcinoma Her-2 germline mutations translational application Khorana score Epidermal growth factor receptors (EGFR) leukocytosis RCC MICROSATELLITE methylation epidermal growth factor receptor 2 plus cisplatin Fox Chase Cancer Center kidney cancer Disease control therapeutic strategy dna methylation analogs & derivatives Pfizer and Bristol-Myers Squibb and has received institutionally Novartis Combined Modality Therapy Neoplasm Metastasis clinical trials manuscript Male clonal expansion Tumors renal cell Female organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those Biological organs tumor-suppressor gene Biochemistry & Molecular Biology gene DNA damage response colorectal-cancer transitional cell carcinoma muscle invasion next-generation sequencing e-cadherin biomarkers checkpoint blockade CIMP aberrant promoter Whole-organ map prognosis and diagnosis epidermal growth factor receptor Epidermal growth factor receptor Oncology hematuria repair founder mutation Adult early detection AstraZeneca and Merck directed clinical trial support from Bristol-Myers Squibb hospital type rapamycin Middle Aged MUTATIONS Chemotherapy chemotherapy survival 80 and over Aged Cisplatin prostate cancer next generation sequencing Radiation Therapy Oncology Group (RTOG) Transitional Cell Carcinoma Ctla-4 genitourinary cancer Immunostaining field effect promoter hypermethylation Genetics & Heredity cancer surveillance mammalian target DNA METHYLATION Pd-1 mouse model screening surgical volume penile metastasis DNA methylation Muscle Neoplasms chemoresponse in-vitro gemcitabine plus cisplatin therapy Treatment Outcome CELL CARCINOMA circulating tumor DNA extended prophylaxis doxorubicin HUMAN COLON methods Urothelial disclosed No writing assistance was utilized in the production of this quality measures Radiotherapy HYPERMETHYLATION The authors have no other relevant affiliations or financial involvement with any penile carcinoma cpg-island methylation BLADDER-CANCER early cancer statistics & numerical data Multivariate analysis gene signature Retrospective Studies COLORECTAL-CANCER institutionally directed clinical trial support from Horizon Pharma ER Plimack clear-cell Methotrexate neoadjuvant Proteins expression urine biopsy tumor suppressor gene carcinoma DNA copy alterations Antineoplastic Combined Chemotherapy Protocols INSTABILITY renal-cell carcinoma mTOR COMPREHENSIVE GENOMIC CHARACTERIZATION Eli Lilly has served on advisory boards and as consultant for Genentech clonal origins hypermethylation Vinblastine growth-factor-beta inhibition